On 24 September 2019 the Dutch Authority for Consumers and Markets (ACM) published its report on the 2018 initiated market study about the effects the introduction of biosimilars had on competition between TNF alfa inhibitors on the Dutch market.

ACM did not establish violations of competition law during its market study, but the ACM did not rule out the possibility that conditional discounts for originator medicines could be found restrictive of competition. ACM identified a number of risks for the sustainability of competition in the long run and stated it will enforce the competition rules if it were to, in the future, receive market indications of e.g. conditional discounts for originator medicines being implemented with the aim of excluding competition on the Dutch market.

Please find the ACM report (in Dutch only) here and our blog on this report (in English) here.